September 11, 2025Cancer MedicineOpen Access

Efficacy of Immune Checkpoint Inhibitors in Combination With Platinum‐Based Doublet Chemotherapy for Extensive‐Stage Small‐Cell Lung Cancer Patients With Eastern Cooperative Oncology Group‐Performance Status 2–3: A Single‐Institution Retrospective Study

View Full Paper

Ask AI

Bookmark

Authors

KSKosuke SakaiOsaka Medical and Pharmaceutical University SIShigeru IshiiSocial Insurance Saitama Chuo Hospital SYShin YokosukaSocial Insurance Saitama Chuo Hospital

Discussion

Member takes

Implication

Retrospective analysis shows improved survival and response rates in extensive-stage small-cell lung cancer patients with poor performance status, suggesting chemoimmunotherapy efficacy.

Key Points

Adding immune checkpoint inhibitors to chemotherapy significantly improved overall survival in patients with ECOG performance status 2-3.
Patients treated with immune checkpoint inhibitors showed an objective response rate of 93.3%, compared to 56.3% in those untreated with ICIs.
In this single-institution study, a total of 74 patients were evaluated over a follow-up period extending to February 2024, enhancing the scope of findings.
Results underline the potential for chemoimmunotherapy to offer new treatment avenues for extensive-stage small-cell lung cancer beyond conventional trial settings.

Cite This Study

Sakai et al. (2025) studied this question.

synapsesocial.com/papers/68d41405713b0b5dfea623fc https://doi.org/10.1002/cam4.71136

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis shows improved survival and response rates in extensive-stage small-cell lung cancer patients with poor performance status, suggesting chemoimmunotherapy efficacy.

Efficacy of Immune Checkpoint Inhibitors in Combination With Platinum‐Based Doublet Chemotherapy for Extensive‐Stage Small‐Cell Lung Cancer Patients With Eastern Cooperative Oncology Group‐Performance Status 2–3: A Single‐Institution Retrospective Study

Discussion

Member takes

Implication

Key Points

Cite This Study

Efficacy of Immune Checkpoint Inhibitors in Combination With Platinum‐Based Doublet Chemotherapy for Extensive‐Stage Small‐Cell Lung Cancer Patients With Eastern Cooperative Oncology Group‐Performance Status 2–3: A Single‐Institution Retrospective Study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider